In Situ Hybridization Market Size To Reach $2.55 Billion By 2030

In Situ Hybridization Market Growth & Trends

The global in situ hybridization market size is expected to reach USD 2.55 billion by 2030, registering a CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. Situ Hybridization (ISH) is extensively utilized for research and clinical applications of diagnostics. ISH is a popular approach among researchers as it aids in determining the relationship between the distribution of specific nucleic acids and the target gene protein products. Hence, expanding the scope of ISH in applications is accelerating and leading to further research.

The increasing awareness about ISH techniques and their usage encourages researchers to employ the techniques for various applications. For instance, the CEO of MultiplexDX stated in an interview with Elsevier that FISH technology can contribute breakthrough information for early drug development and personalized treatment. A growing number of people in developed countries are opting for personalized treatment owing to an increase in awareness, thus boosting market demand.

Furthermore, reimbursement schemes being made available in developed economies have led to an increase in demand for this diagnosis. The demand continues to increase as the majority of the public can now afford it due to the recent expansion through insurance coverage. For instance, Medicare is the largest market player in the U.S., which provides care for those aged 65 years and above, irrespective of their income and medical history.

Owing to the COVID-19 pandemic, the demand side showcased a positive impact on the ISH market as various researchers employed the technique on COVID-19-infected cells. Research published in July 2020, considered 8 autopsy lungs, 10 kidney biopsies, and 1 placenta from COVID-19-infected patients with ISH assay and RNA probes.

COVID-19 positive results showed in all 8 lungs and the placenta by ISH, but not in the kidney samples. The assay showcases a sensitive and specific technique for detecting the virus from tissue samples. Similarly, Advanced Cell Diagnostics, Inc., introduced RNAscope technology to support COVID-19 research.

The growing strategic initiatives by the companies are anticipated to boost the ISH market growth. Key players are introducing novel products in the market to strengthen their portfolios. For instance, in March 2021, F. Hoffmann-La Roche launched DISCOVERY Green HRP chromogen detection kit to expand the multiplexing capability of in situ hybridization and immunohistochemistry.

On the other hand, molecular diagnostics renders accurate & effective results and has indispensable applications in the field of diagnosis. However, the high manufacturing cost of FISH assays and the high amount of capital required for specialized assembly plants & maintenance of instruments used in FISH imaging are likely to limit revenue generation.

 Request a free sample copy or view report summary: In Situ Hybridization Market Report

In Situ Hybridization Market Report Highlights

• By technology, the CISH segment is projected to expand at the fastest growth rate during the forecast period. Since the reagents used in CISH are more stable, the sample can be stored for a longer duration and can be examined multiple times

• By probe, the DNA segment is anticipated to have the fastest growth rate during the forecast period. Owing to the increasing incidence of diseases associated with chromosomal aberrations, such as genetic abnormalities and cancer

• By product, the services segment is anticipated to have the fastest-growing CAGR between 2024 to 2030. Increasing outsourcing to ensure high adherence to quality standards and improve operational functionalities contributes to the lucrative growth.

In Situ Hybridization Market Segmentation

Grand View Research has segmented the global in situ hybridization market based on technology, probe type, product, application, end-use, and region:

In Situ Hybridization Technology Outlook (Revenue, USD Million, 2018 - 2030) 

• FISH

• CISH

In Situ Hybridization Probe Outlook (Revenue, USD Million, 2018 - 2030) 

• DNA

• RNA

In Situ Hybridization Product Outlook (Revenue, USD Million, 2018 - 2030) 

• Instruments

• Consumables & Accessories

• Software

• Services

In Situ Hybridization Application Outlook (Revenue, USD Million, 2018 - 2030) 

• Cancer

• Cytogenetics

• Developmental Biology

• Infectious Diseases

• Others

In Situ Hybridization End-use Outlook (Revenue, USD Million, 2018 - 2030) 

• Hospitals & Diagnostic Laboratories

• CROs

• Academic & Research Institutes

• Others

In Situ Hybridization Regional Scope Outlook (Revenue, USD Million, 2018 - 2030) 

• North America

• U.S.

• Canada

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• South Korea

• Australia

• Thailand

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait 

List of Key Players in the In-Situ Hybridization Market

• Thermo Fisher Scientific, Inc.

• Abbott

• PerkinElmer, Inc.

• BioView

• Agilent Technologies, Inc.

• Merck KGaA

• Bio-Rad Laboratories, Inc.